Latest news with #EuronextAmsterdam
Miami Herald
2 days ago
- Business
- Miami Herald
Netherlands to vote on October 29 after government falls
The Netherlands will hold a general election on October 29 after far-right leader Geert Wilders pulled his Freedom Party out of the Dutch government earlier this week. The Minister of the Interior Judith Uitermark posted the date on X Friday. Wilders pulled the plug on the coalition after his partners rejected his latest proposals to curb immigration, plunging the European nation into months of uncertainty. A caretaker government is now in place after Prime Minister Dick Schoof tendered his resignation. The fall of the coalition will negatively impact investment and consumption, Olaf Sleijpen, the Dutch central bank's executive director of monetary affairs and financial stability, warned Friday. Even after an election is held, coalitions can take months to build, meaning the Netherlands faces a lengthy period of a government which cannot deal with the most sensitive topics. The parliament is expected to vote on a list of policy areas deemed "controversial" that the caretaker administration should avoid until after the elections. Schoof on Wednesday urged lawmakers to consider international security, tariffs and the budget among uncontroversial topics to be handled by the caretaker Cabinet. There was little reaction from the AEX Index, a gauge tracking the 25 largest stocks listed on the Euronext Amsterdam, which was trading flat as at 12:55pm CET. ---------- -With assistance from Patrick Van Oosterom. Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.
Yahoo
2 days ago
- Business
- Yahoo
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025
Vivoryon Therapeutics N.V. Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025 Halle (Saale) / Munich, Germany, June 6, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that meta-analysis data for its lead drug in development, varoglutamstat, was presented at the 62nd ERA Congress of the European Renal Association in Vienna, Austria, today, June 6, 2025. 'We are delighted that the results of the Phase 2 program were accepted for presentation at the ERA 2025 congress. This allowed Vivoryon to share the outstanding improvements of varoglutamstat on kidney function (eGFR) with the scientific and medical expert community in the kidney space,' said Frank Weber, MD, CEO of Vivoryon. Presentation Highlights Varoglutamstat is a first-in-class glutaminyl cyclase (QPCT/L) inhibitor with potent anti-inflammatory and anti-fibrotic effects. VIVIAD and VIVA-MIND, two independent Phase 2 studies in the EU and U.S. showed a statistically significant and clinically meaningful improvement in a prospectively defined kidney function parameter, eGFR, in an elderly patient population. This improvement was consistent in both trials independently, replicated in the meta-analysis and pooled analysis, and provides converging evidence for this finding. Statistically significant differences between varoglutamstat and placebo were first observed at week 24 and were sustained until week 96. The meta-analysis also confirmed a substantially larger effect size in study participants with diabetes compared to those without diabetes. The next step is planned to be a dedicated Phase 2b trial in patients with diabetic kidney disease (patients with diabetes and chronic kidney disease stage 3b/4). The main goal will be to investigate the efficacy on eGFR in this patient population and to obtain additional information on a potential effect on proteinuria and other kidney specific markers. Presentation Details Date: June 6, 2025 Presentation time: 8:15 am CEST as part of the focused oral session Title: Varoglutamstat improves eGFR and offers a new approach to treat diabetic kidney disease (DKD): meta-analysis from two independent Phase 2 studies Venue: Vienna, Austria Presenter: Frank Weber, MD, CEO of Vivoryon Therapeutics ### About Vivoryon Therapeutics N.V. Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon's most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease.
Yahoo
3 days ago
- Business
- Yahoo
Share Buyback Transaction Details May 29 – June 4, 2025
PRESS RELEASE Share Buyback Transaction Details May 29 – June 4, 2025 Alphen aan den Rijn – June 5, 2025 - Wolters Kluwer (Euronext: WKL), a global leader in professional information solutions, software and services, today reports that it has repurchased 225,452 of its own ordinary shares in the period from May 29, 2025, up to and including June 4, 2025, for €35.2 million and at an average share price of €155.93. These repurchases are part of the share buyback program announced on February 26, 2025, under which we intend to repurchase shares for up to € 1 billion during 2025. The cumulative amounts repurchased in the year to date under this program are as follows: Share Buyback 2025 Period Cumulative shares repurchased in period Total consideration(€ million) Average share price(€) 2025 to date 2,750,306 427.5 155.43 For the period starting May 8, 2025, up to and including July 28, 2025, we have engaged third parties to execute €350 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company's Articles of Association. Shares repurchased are added to and held as treasury shares and will be used for capital reduction purposes through share cancelation. Further information is available on our website: Download the share buyback transactions excel sheet for detailed individual transaction information. Weekly reports on the progress of our share repurchases. Overview of share buyback programs. For more information about Wolters Kluwer, please visit: ### About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information solutions, software and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX, Euro Stoxx 50 and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY). For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram. Media Investors/Analysts Stefan Kloet Meg Geldens Associate Director Vice President Global Communications Investor Relations press@ ir@ Forward-looking Statements and Other Important Legal InformationThis report contains forward-looking statements. These statements may be identified by words such as 'expect', 'should', 'could', 'shall' and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; conditions created by pandemics; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer's businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Elements of this press release contain or may contain inside information about Wolters Kluwer within the meaning of Article 7(1) of the Market Abuse Regulation (596/2014/EU). Trademarks referenced are owned by Wolters Kluwer N.V. and its subsidiaries and may be registered in various countries. Attachment 2025.06.05 Share Buyback Transactions May 29 - Jun 4 2025Sign in to access your portfolio
Yahoo
5 days ago
- Business
- Yahoo
Jacobi Bitcoin ETF's Lowers Entry Barriers Allowing European Retail Investors to Jump In
Jacobi Asset Management has lowered entry barriers for its bitcoin BTC exchange-traded fund (ETF), allowing European retail investors to participate for the first time. This follows the removal of professional-only and minimum investment requirements by the Guernsey regulator. Originally launched in 2023 on Euronext Amsterdam, the ETF was designed to meet institutional grade standards for security, transparency, and compliance. Until now, access was limited to professional investors in line with regulatory requirements and market maturity. However, with the evolving financial ecosystem and growing institutional and governmental acceptance of bitcoin, Jacobi has worked closely with partners including Collas Crill, Midshore Consulting, and Sigma Asset Management to secure the removal of restrictions on retail participation. This strategic shift enables broader access to the ETF through regulated brokerage and investment platforms, subject to national regulations, significantly enhancing market inclusivity. The fund continues to be safeguarded by Zodia Custody, which provides secure institutional grade custody solutions. 'Our fund was designed from day one with a regulated, institutional-grade structure that investors could trust and were familiar with. Now, with greater regulatory alignment and growing public interest, we're delighted to expand access to all investors across eligible jurisdictions,' said Peter Lane, CEO of Jacobi Asset Management. "This marks a milestone not only for Jacobi, but also for Guernsey's positioning as a forward-looking digital asset jurisdiction," he added. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
21Shares Launches 21Shares Hedera ETP (HDRA) on Euronext
New ETP offers regulated exposure to one of the most scalable and sustainable distributed ledger technologies Zurich, 3 June 2025 – 21Shares AG ('21Shares'), one of the world's largest issuers of crypto exchange-traded products (ETPs), today announced the launch of the 21Shares Hedera ETP (Ticker: HDRA). The product is now listed on Euronext Amsterdam (USD) and Euronext Paris (EUR), offering investors simple, transparent, and regulated access to Hedera's enterprise-grade DLT (distributed ledger technology). Exchange Product Name Ticker ISIN Fee Euronext Paris and Euronext Amsterdam 21Shares Hedera ETP HDRA CH1456607683 2.50% The 21Shares Hedera ETP provides 100% physically backed exposure to HBAR, the native token of the Hedera network. It allows investors to gain institutional-grade access, directly through traditional bank or brokerage accounts, to one of the most energy-efficient and scalable distributed ledger technologies available today. 'With its unique architecture, strong governance model, and real-world adoption, Hedera stands out as one of the most advanced distributed ledger technologies on the market,' said Duncan Moir, President at 21Shares and Board Member at Hedera Hashgraph LLC. 'By launching the 21Shares Hedera ETP, we are enabling both institutional and retail investors to participate in the growing Hedera ecosystem through a fully regulated, transparent investment vehicle.' Hedera is an open-source distributed ledger designed for real-world innovation and enterprise use. It is governed by a global council of up to 39 renowned institutions, including Google, IBM, LG, Dell, EDF, and Deutsche Telekom, operating under legally binding, transparent terms. This governance model emphasises trust, resilience, and long-term stability – redefining decentralisation for scalable, mainstream adoption. 'As more institutions seek secure ways to access digital assets, 21Shares continues to lead the way by bridging traditional finance and crypto with clarity and confidence,' said Gregg Bell, Chief Business Officer at Hedera Foundation. 'This collaboration gives investors a straightforward way to access HBAR and brings them closer to a network trusted by leading institutions worldwide.' Unlike traditional blockchains, Hedera leverages its novel Hashgraph consensus mechanism that delivers industry-leading performance. It supports up to 500,000 transactions per second under testing conditions, offers predictable, fixed fees in USD, and consumes just 0.000003 kWh per transaction – making it 1,000 times more energy-efficient than a typical Visa transaction. For more information, visit to editors About 21Shares 21Shares is one of the world's leading cryptocurrency exchange traded product providers and offers the largest suite of crypto ETPs in the market. The company was founded to make cryptocurrency more accessible to investors, and to bridge the gap between traditional finance and decentralized finance. 21Shares listed the world's first physically-backed crypto ETP in 2018, building a seven-year track record of creating crypto exchange-traded funds that are listed on some of the biggest, most liquid securities exchanges globally. Backed by a specialized research team, proprietary technology, and deep capital markets expertise, 21Shares delivers innovative, simple and cost-efficient investment solutions. 21Shares is a member of a global leader in decentralized finance. For more information, please visit Media ContactMatteo About Hedera Foundation Hedera Foundation fuels the innovation and development of public-network applications on the Hedera network. By providing grants, technical assistance, and community support, we empower projects that leverage Hedera's fast, secure, and sustainable ledger to solve real-world problems. Learn more at DISCLAIMER This document is not an offer to sell or a solicitation of an offer to buy or subscribe for securities of 21Shares AG in any jurisdiction. Neither this document nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever or for any other purpose in any jurisdiction. Nothing in this document should be considered investment advice. This document and the information contained herein are not for distribution in or into (directly or indirectly) the United States, Canada, Australia or Japan or any other jurisdiction in which the distribution or release would be unlawful. This document does not constitute an offer of securities for sale in or into the United States, Canada, Australia or Japan. The securities of 21Shares AG to which these materials relate have not been and will not be registered under the United States Securities Act of 1933, as amended (the 'Securities Act'), and may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There will not be a public offering of securities in the United States. Neither the US Securities and Exchange Commission nor any securities regulatory authority of any state or other jurisdiction of the United States has approved or disapproved of an investment in the securities or passed on the accuracy or adequacy of the contents of this presentation. Any representation to the contrary is a criminal offence in the United States. Within the United Kingdom, this document is only being distributed to and is only directed at: (i) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the 'Order'); or (ii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as 'relevant persons'); or (iii) persons who fall within Article 43(2) of the Order, including existing members and creditors of the Company or (iv) any other persons to whom this document can be lawfully distributed in circumstances where section 21(1) of the FSMA does not apply. The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. Exclusively for potential investors in any EEA Member State that has implemented the Prospectus Regulation (EU) 2017/1129 the Issuer's Base Prospectus (EU) is made available on the Issuer's website under The approval of the Issuer's Base Prospectus (EU) should not be understood as an endorsement by the SFSA of the securities offered or admitted to trading on a regulated market. Eligible potential investors should read the Issuer's Base Prospectus (EU) and the relevant Final Terms before making an investment decision in order to understand the potential risks associated with the decision to invest in the securities. You are about to purchase a product that is not simple and may be difficult to understand. This document constitutes advertisement within the meaning of the Prospectus Regulation (EU) 2017/1129 and the Swiss Financial Services Act (the 'FinSA') and not a prospectus. The 2024 Base Prospectus of 21Shares AG has been deposited pursuant to article 54(2) FinSA with BX Swiss AG in its function as Swiss prospectus review body within the meaning of article 52 FinSA. The 2024 Base Prospectus and the key information document for any products may be obtained at 21Shares AG's website ( or ### Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
